MK 1454

Drug Profile

MK 1454

Alternative Names: MK-1454

Latest Information Update: 30 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck & Co
  • Developer Merck & Co; Merck Sharp & Dohme
  • Class Antineoplastics; Immunotherapies; Nucleotides
  • Mechanism of Action MPYS-protein-stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Lymphoma; Solid tumours

Most Recent Events

  • 01 Feb 2017 Phase-I clinical trials in Lymphoma and Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Combination therapy) in France and United Kingdom (Intratumoural) after February 2017 (NCT03010176)
  • 01 Feb 2017 Phase-I clinical trials in Solid tumours and Lymphoma (Monotherapy, Combination therapy, Late-stage disease, Metastatic disease) in USA and Israel (Intratumoural) (NCT03010176)
  • 01 Jan 2017 Merck Sharp and Dohme plans a phase I trial for Solid tumours and Lymphoma (Combination therapy, Monotherapy, Late-stage disease, Metastatic disease) in USA (NCT03010176)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top